pharmaphorum

FEBRUARY 23, 2022

Takeda has forged another alliance as it continues a push into gene therapy, agreeing a deal worth up to $2 billion with Code Biotherapeutics for opt-in rights to four candidates for rare diseases. The post Takeda grows in gene therapies again with $2bn Code Bio deal appeared first on. Last October it signed a $3.6 billion-plus.

Gene Therapy 94

Gene Therapy Gene Gene Sequencing Immune Response 94

pharmaphorum

FEBRUARY 22, 2021

Bluebird Bio’s decision to hit pause on the launch of Zynteglo for beta thalassaemia after two cases of cancer were seen in a clinical trial could see fears over the safety of viral vectors used to deliver gene therapies resurface. . million in Europe.

Gene Therapy 52

Gene Therapy Gene Gene Sequencing Gene Expression 52

pharmaphorum

MAY 18, 2021

.” The interim phase 2 results show that two doses of the plant-derived jab stimulated neutralising antibody levels that are around 10 times higher than those in a panel of sera from patients recovering from COVID-19, with a similar response seen in adults and the elderly.

Immune Response 62

Immune Response Vaccination Vaccine Gene Sequencing 62

Drug Discovery World

FEBRUARY 5, 2024

Brian Gladsden, CEO, Mosaic Therapeutics “The industry has already made tremendous strides in targeted drug discovery in oncology, particularly as the industry moves further away from simply looking at tumour histology and relying more on cancer gene sequencing.

Research 116

Research Drug Delivery Systems Gene Sequencing Trials 116